Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 9/20 | 0.44 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526333 | 0.90 | MAOB (0.47) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4529910 | 0.90 | RAB9A (0.53) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4554546 | 0.89 | FFAR1 (0.46) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4523255 | 0.88 | NPC1 (0.51) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4529815 | 0.88 | MAOB (0.45) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4527045 | 0.87 | MRGPRX4 (0.55) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4554536 | 0.86 | FFAR1 (0.43) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4515791 | 0.85 | RAB9A (0.45) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL13637818 | 0.85 | MAOB (0.45) | MAOBRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4554556 | 0.85 | MAOB (0.50) | MAOBRAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | claimed |
| EP-2124563-B1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2124563-B1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2124563-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| WO-2008076752-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | MAOB 1031/4885RAB9A 3194/4885NPC1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.